Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: A phase III metastatic castration resistant prostate cancer trial

Amir Goldkorn*, Benjamin Ely, Catherine M. Tangen, Yu Chong Tai, Tong Xu, Hongli Li, Przemyslaw Twardowski, Peter J. Van Veldhuizen, Neeraj Agarwal, Michael A. Carducci, J. Paul Monk, Mark Garzotto, Philip C. Mack, Primo Lara, Celestia S. Higano, Maha Hussain, Nicholas J. Vogelzang, Ian M. Thompson, Richard J. Cote, David I. Quinn

*Corresponding author for this work

Research output: Contribution to journalArticle

26 Scopus citations

Abstract

Circulating tumor cells (CTC) are promising biomarkers in metastatic castration resistant prostate cancer (mCRPC), and telomerase activity (TA) is a recognized cancer marker. Therefore, we hypothesized that CTC TA may be prognostic of overall survival (OS) in mCRPC. To test this, we used a novel Parylene-C slot microfilter to measure live CTC TA in S0421, a phase III SWOG-led therapeutic trial. Blood samples underwent CTC capture and TA measurement by microfilter, as well as parallel enumeration by CellSearch (Janssen/J&J). Cox regression was used to assess baseline (pre-treatment) TA versus OS, and recursive partitioning was used to explore potential prognostic subgroups and to generate Kaplan-Meier (KM) OS curves. Samples were obtained from 263 patients and generated 215 TA measures. In patients with baseline CTC count ≥5 (47% of patients), higher CTC TA was associated with hazard ratio 1.14 (p50.001) for OS after adjusting for other clinical covariates including CTC counts and serum PSA at study entry. Recursive partitioning identified new candidate risk groups with KM OS curve separation based on CTC counts and TA. Notably, in men with an intermediate range baseline CTC count (6-54 CTCs/7.5 ml), low versus high CTC TA was associated with median survival of 19 versus 12 months, respectively (p50.009). Baseline telomerase activity from CTCs live-captured on a new slot microfilter is the first CTC-derived candidate biomarker prognostic of OS in a large patient subgroup in a prospective clinical trial. CTC telomerase activity thus merits further study and validation as a step.

Original languageEnglish (US)
Pages (from-to)1856-1862
Number of pages7
JournalInternational Journal of Cancer
Volume136
Issue number8
DOIs
StatePublished - Apr 15 2015

Keywords

  • Biomarker
  • Circulating tumor cells
  • Prognosis
  • Prostate cancer
  • Telomerase activity

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: A phase III metastatic castration resistant prostate cancer trial'. Together they form a unique fingerprint.

  • Cite this

    Goldkorn, A., Ely, B., Tangen, C. M., Tai, Y. C., Xu, T., Li, H., Twardowski, P., Van Veldhuizen, P. J., Agarwal, N., Carducci, M. A., Monk, J. P., Garzotto, M., Mack, P. C., Lara, P., Higano, C. S., Hussain, M., Vogelzang, N. J., Thompson, I. M., Cote, R. J., & Quinn, D. I. (2015). Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: A phase III metastatic castration resistant prostate cancer trial. International Journal of Cancer, 136(8), 1856-1862. https://doi.org/10.1002/ijc.29212